This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Aluminum oxide
- DrugBank Accession Number
- DB11342
- Background
Aluminum oxide has a chemical formula Al2O3. It is amphoteric in nature, and is used in various chemical, industrial and commercial applications. It is considered an indirect additive used in food contact substances by the FDA.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Aluminum oxide (DB11342)
- Weight
- Average: 101.96
Monoisotopic: 101.9478209 - Chemical Formula
- Al2O3
- Synonyms
- Aluminium oxide
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination as diagnostic agent Bleeding Combination Product in combination with: Sodium molybdate (DB14496), Technetium Tc-99m pertechnetate (DB09314) •••••••••••• •••••••• Used in combination as diagnostic agent Brain swelling Combination Product in combination with: Sodium molybdate (DB14496), Technetium Tc-99m pertechnetate (DB09314) •••••••••••• •••••••• Used in combination as diagnostic agent Ectopic intestinal mucosa Combination Product in combination with: Technetium Tc-99m pertechnetate (DB09314), Sodium molybdate (DB14496) •••••••••••• •••••••• Used in combination as diagnostic agent Meckel diverticulum Combination Product in combination with: Sodium molybdate (DB14496), Technetium Tc-99m pertechnetate (DB09314) •••••••••••• •••••••• Used in combination as diagnostic agent Occult gi bleeding Combination Product in combination with: Sodium molybdate (DB14496), Technetium Tc-99m pertechnetate (DB09314) •••••••••••• •••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareCarbamazepine Aluminum oxide can cause a decrease in the absorption of Carbamazepine resulting in a reduced serum concentration and potentially a decrease in efficacy. Chenodeoxycholic acid Aluminum oxide can cause a decrease in the absorption of Chenodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Cholic Acid Aluminum oxide can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Deferasirox Aluminum oxide can cause a decrease in the absorption of Deferasirox resulting in a reduced serum concentration and potentially a decrease in efficacy. Dehydrocholic acid Aluminum oxide can cause a decrease in the absorption of Dehydrocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image ALUMINIUM HYDROXIDE MIXTURE BP 4% w/w Suspension 4 % w/w Oral SUNWARD PHARMACEUTICAL PRIVATE LIMITED 1989-04-21 Not applicable Singapore 
ALUTACID ANTACID MIXTURE 4% w/w Suspension 4 % w/w Oral ICM PHARMA PTE. LTD. 1996-03-07 Not applicable Singapore Brasivol Fine Cream 38.2 % Topical Stiefel Laboratories, Inc. 1966-12-31 2000-01-07 Canada 
Brasivol Medium Cream 52.2 % Topical Stiefel Laboratories, Inc. 1966-12-31 2000-01-07 Canada Vfb Bio Peel Powder 6.5 mg/1g Topical General Bio Co., Ltd. 2014-12-09 2019-09-30 US 
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image POLGENTEC 2-120 GBQ GENERADOR DE RADIONUCLEIDOS Aluminum oxide (2 g) + Sodium molybdate (0 GBq) + Technetium Tc-99m sodium pertechnetate (120 GBq) Solution Intravenous ISOMEDIX TECHNOLOGY S.A.S. 2013-09-19 Not applicable Colombia 
- Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Vfb Bio Peel Aluminum oxide (6.5 mg/1g) Powder Topical General Bio Co., Ltd. 2014-12-09 2019-09-30 US
Categories
- ATC Codes
- D10AX04 — Aluminium oxide
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as post-transition metal salts. These are inorganic halogenic compounds in which the heaviest metal atom is a post-transition metal.
- Kingdom
- Inorganic compounds
- Super Class
- Mixed metal/non-metal compounds
- Class
- Post-transition metal salts
- Sub Class
- Not Available
- Direct Parent
- Post-transition metal salts
- Alternative Parents
- Miscellaneous mixed metal/non-metals / Inorganic salts
- Substituents
- Inorganic post-transition metal salt / Inorganic salt / Miscellaneous mixed metal/non-metal
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- LMI26O6933
- CAS number
- 1344-28-1
- InChI Key
- PNEYBMLMFCGWSK-UHFFFAOYSA-N
- InChI
- InChI=1S/2Al.3O/q2*+3;3*-2
- IUPAC Name
- dialuminium(3+) ion trioxidandiide
- SMILES
- [O--].[O--].[O--].[Al+3].[Al+3]
References
- General References
- Not Available
- External Links
- PubChem Compound
- 9989226
- PubChem Substance
- 347827970
- ChemSpider
- 8164808
- 615
- ChEMBL
- CHEMBL3707210
- Wikipedia
- Aluminium_oxide
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Suspension Oral 4 % w/w Cream Topical 38.2 % Cream Topical 52.2 % Solution Intravenous Powder Topical 6.5 mg/1g - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP -0.65 Chemaxon pKa (Strongest Acidic) 15.7 Chemaxon pKa (Strongest Basic) -1.8 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 1 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 0 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 13.11 m3·mol-1 Chemaxon Polarizability 0.95 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at December 03, 2015 16:52 / Updated at May 21, 2021 10:22